Joost G E Janzing
Overview
Explore the profile of Joost G E Janzing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jakobs K, van den Brule-Barnhoorn K, van Lieshout J, Janzing J, Cahn W, Kievit W, et al.
Contemp Clin Trials Commun
. 2025 Feb;
44:101418.
PMID: 39897941
Background: It is well established that patients with severe mental illness and those treated with atypical antipsychotics (AAPs) are at an increased risk of cardiovascular disease. However, primary care currently...
2.
Vos C, Coenen M, Ter Hark S, Aarnoutse R, Schellekens A, Janzing J
Eur Neuropsychopharmacol
. 2024 Sep;
89:56-57.
PMID: 39341084
No abstract available.
3.
Jakobs K, van den Brule-Barnhoorn K, van Lieshout J, Janzing J, Cahn W, van den Muijsenbergh M, et al.
Sci Rep
. 2024 Aug;
14(1):18659.
PMID: 39134577
No abstract available.
4.
Arnold P, Janzing J, Hommersom A
Drug Discov Today
. 2024 Jun;
29(8):104068.
PMID: 38925472
Finding the right antidepressant for the individual patient with major depressive disorder can be a difficult endeavor and is mostly based on trial-and-error. Machine learning (ML) is a promising tool...
5.
Jakobs K, van den Brule-Barnhoorn K, van Lieshout J, Janzing J, Cahn W, van den Muijsenbergh M, et al.
Sci Rep
. 2024 May;
14(1):12367.
PMID: 38811680
General practitioners (GPs) are often unaware of antipsychotic (AP)-induced cardiovascular risk (CVR) and therefore patients using atypical APs are not systematically monitored. We evaluated the feasibility of a complex intervention...
6.
Ter Hark S, Coenen M, Vos C, Aarnoutse R, Nolen W, Birkenhager T, et al.
Transl Psychiatry
. 2024 Apr;
14(1):198.
PMID: 38671038
No abstract available.
7.
Ter Hark S, Coenen M, Vos C, Aarnoutse R, Nolen W, Birkenhager T, et al.
Transl Psychiatry
. 2024 Mar;
14(1):132.
PMID: 38431658
Psychotic depression is a severe and difficult-to-treat subtype of major depressive disorder for which higher rates of treatment-resistant depression were found. Studies have been performed aiming to predict treatment-resistant depression...
8.
Kummeling J, Vermeulen-Kalk K, Souverein V, van Dongen L, Oomens W, Janzing J, et al.
Clin Neuropsychiatry
. 2023 Dec;
20(5):453-461.
PMID: 38089734
Objective: Several instruments are available for measuring (aspects of) adaptive functioning, but knowledge is lacking about which is best to use to monitor patients with etiologically homogeneous neurodevelopmental disorders. In...
9.
Vos C, Birkenhager T, Nolen W, Van den Broek W, Ter Hark S, Schellekens A, et al.
J Clin Psychopharmacol
. 2023 Nov;
43(6):486-492.
PMID: 37930199
Background: Since insomnia and depression are interrelated, improved sleep early in antidepressant pharmacotherapy may predict a positive treatment outcome. We investigated whether early insomnia improvement (EII) predicted treatment outcome in...
10.
Vos C, Ter Hark S, Schellekens A, Spijker J, van der Meij A, Grotenhuis A, et al.
JAMA Netw Open
. 2023 May;
6(5):e2312443.
PMID: 37155164
Importance: Evidence of the clinical benefit of pharmacogenetics-informed treatment (PIT) with antidepressants is still limited. Especially for tricyclic antidepressants (TCAs), pharmacogenetics may be of interest because therapeutic plasma concentrations are...